🔗 Share this article

A shadow market for unlicensed slimming medications is being driven by social media fitness personalities and vendors on communication apps, according to recent findings.

Investigational Drug Gaining Popularity Online

The experimental drug, which is still in research studies, is being advertised by social media influencers for its supposed fat-burning effects. Viewers are urged to contact these profiles directly for supplier links, while also obtaining promotional offers.

Active Trade on Social Networks

Separately, a flourishing market exists on messaging services, where communities with thousands of participants share comparison images, injection guides and assertions of rapid UK delivery. Vendors promote the drug there before directing customers to other platforms for purchases.

Understanding The Experimental Drug

Retatrutide is an experimental injectable created by US drugmaker Eli Lilly. The drug targets three gut hormones – GLP-1, GIP and glucagon. Preliminary studies suggest it could assist patients lose up to 25% of their total weight. Nicknamed the “triple G”, the substance is being promoted online as the next Ozempic.

Medical Professionals Voice Worries

Nevertheless, doctors and pharmacists have cautions that the sale of what is still an unlicensed drug in the United Kingdom is a cause for concern and could result in users injecting substances of unknown origin.

Some professionals said the popularity for the experimental drug could be linked to the rising cost of approved weight loss products such as Mounjaro.

Regulatory Position and Implementation

Selling the unapproved drug on social media or messaging apps is prohibited in the UK, as it is an unapproved medication that cannot be promoted or supplied for human use under the Human Medicines Regulations 2012.

Several content creators try to sidestep the regulations by calling to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted substance, but promotion and distribution can still violate medicines, marketing, and consumer regulations, potentially leading to fines, prosecution or prison.

Platform Reaction and Content Removal

Based on the social media company, the platform has taken down violative content and banned related hashtags and query recommendations. The organization stated it was committed to keeping the platform safe and allocating resources in strengthening compliance measures.

Online Marketplace Activities

Investigations also discovered groups with up to nine thousand participants selling the experimental drug using Telegram's built-in discovery tool, which operates like a online catalog. Typing “retatrutide” immediately displays channels with numerous of users, populated with images of slimming results, glowing testimonials and detailed guides for preparing or injecting at residence.

After moments of joining one group, a vendor posted contact information, where the majority of transactions occur. The vendor provided an instruction manual and promised delivery within 48 hours. When asked whether the product was genuine, one vendor said: “You can’t be sure.” Another shared a image of a supposed testing documentation. None inquired about weight, medical conditions or past usage.

Item Details and Costs

Inside these communities, messages display dark colored packages with Royal Mail stickers, stating to contain fresh supplies. One communication stated: “It took eight of us to load them this morning.”

Customers can choose between powder vials, mixed at home with purified liquid, or pre-filled pens usually sold at 160 pounds for 20 milligrams. When questioned how long a pen should be used, sellers give contradictory answers ranging from a several days to “depends on your body”.

Service Moderation and Security Actions

A representative for the messaging service said it actively moderated harmful content on its platform including material that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Medical Professional Cautions

“Individuals are injecting substances they can’t verify. Even if the research behind this drug is sound, these online products may not include what they claim,” said Jason Murphy, the director of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to recent cost increases for approved weight-loss drugs such as Mounjaro. “With prices rising, individuals are turning to social media. But fake injections are highly dangerous. You can’t be certain what’s contained or whether the environment they were made in was sterile,” she explained.

Her team has already seen individuals harmed by self-injection from unverified sources. “We understand the frustration, but buying from messaging apps or WhatsApp is taking chances with your well-being,” said the doctor. “These materials could be contaminated or incorrectly dosed.”

Manufacturer Statement

A spokesperson from the pharmaceutical company said the substance was in phase 3 clinical trials and had not been evaluated or approved by any regulatory agency globally. “Therefore at this point no one can market [it] for personal consumption,” they explained, adding that any product “falsely representing itself as a company investigational substance not yet authorized … may expose users to potentially serious health risks”.